Methods of treatment using protein binders to irhom2 epitopes
AssigneesSciRhom GmbH, New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special
InventorsMatthias SCHNEIDER, Kerstin SELLE, Jens RUHE, Gisela WESKAMP, Carl BLOBEL
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method for inhibiting or reducing TACE/ADAM17 activity in a human or animal subject. The method comprises administering to the human or animal subject an effective amount for reducing or inhibiting TACE/ADAM 17 activity of a protein binder which, when bound to human iRhom2, binds at least within a region of Loop 1 thereof, or of a nucleic acid that encodes for at least one chain of a protein binder which, when bound to human iRhom2, binds at least within a region of Loop 1 thereof.
Claims16
A method for inhibiting or reducing TACE/ADAM17 activity in a human or animal subject which comprises administering to the human or animal subject an effective amount for reducing or inhibiting TACE/ADAM 17 activity of a protein binder which, when bound to human iRhom2, binds at least within a region of Loop 1 thereof, or of a nucleic acid that encodes for at least one chain of a protein binder which, when bound to human iRhom2, binds at least within a region of Loop 1 thereof.
The method according to claim 1, wherein the protein binder that binds to human iRhom2 competes for binding to human iRhom2 with
- a) an antibody according to any one of claims 8-14, or
- b) an antibody selected from the group consisting of clones #3, #5, #16, #22, #34, #42, #43, #44, #46, #49, #54, #56, or #57
Dependencies are inferred from the claim text.